Allergan PLC never really left the market for biopharmaceutical mergers and acquisitions after it entered into a $160bn merger agreement with Pfizer Inc., but now that the deal has been called off the company is free to buy assets large and small that fit its "growth pharma" focus.
Allergan PLC never really left the market for biopharmaceutical mergers and acquisitions after it entered into a $160bn merger agreement with Pfizer Inc., but now that the deal has been called off the company is free to buy assets large and small that fit its "growth pharma" focus.
Since there always was a chance that the US government would propose new tax rules to prevent the mega-merger, it's...
IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.
The osteogenesis imperfecta drug stumbled in a second interim analysis.
The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.
